PDF下载 分享
[1]徐志伟,周小杰,潘伟,等.miRNA-122作为药源性肝损伤潜在生物标志物可能性研究进展[J].甘肃中医药大学学报,2018,35(02):110-113.[doi:10.16841/j.issn1003-8450.2018.02.29]
 XU Zhiwei,ZHOU Xiaojie,PAN Wei,et al.The research progress of possibility on miRNA-122 as potential biomarker in drug-induced liver injury[J].Journal of Gansu University of Chinese Medicine,2018,35(02):110-113.[doi:10.16841/j.issn1003-8450.2018.02.29]
点击复制

miRNA-122作为药源性肝损伤潜在生物标志物可能性研究进展

参考文献/References:

[1] Grant L M,Rockey D C.Drug-induced liver injury[J].Curr Opin Gastroenterol,2012,28(3):198-202.
[2] 胡琴,刘维,邵宏.药物性肝损伤的药物治疗研究进展[J].中国临床药理学与治疗学,2016,21(2):231-236.
[3] Xu J J,Henstock P V,Dunn M C,et al.Cellular imaging predictions of clinical drug-induced liver injury[J].Toxicol Sci,2008,105(1):97-105.
[4] Lee R C,Feinbaum R L,Ambros V.The celegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity lin-14[J].Cell,1993,75(5):843-854.
[5] Ambros V.The functions of animal microRNAs[J].Nature,2004,431(7006):350-355.
[6] Jopling C L,Norman K L,Sarnow P.Positive and negative modulation of viral and cellular mRNAs by liver-specific micro RNA miR-122[J].Cold Spring Harb Symp Quant Biol,2006,71(1):369-376.
[7] Chang J,Nicolas E,Marks D,et al.MiR-122,a mammalian liver-specific micro RNA,is processed from hcr mRNA and may down regulate the high affinity cationic amino acid transporter CAT-1[J].RNA Biol,2004,1(2):17-24.
[8] Wienholds E,Kloosterman W P,Miska E,et al.MicroRNA expression in zebra fish embryonic development[J].Science,2005,309:310-311.
[9] Vincent R,Sanyal A.Recent advances in understanding of NAS microRNAs as both biochemical markers and players[J].Curr Pathobiol Rep,2014,2(3):109-116.
[10] Esau C,Davis S,Murray S F,et al.miRNA-122 regulation of lipid metabolism revealed by in vivo antisense targeting[J].Cell Metab,2006,3(2):87-98.
[11] Kim V N,Nam J W.Genomics of microRNA[J].Trends Genet,2006,22(3):165-173.
[12] Hulsmans M,Holvoet P.MicroRNA-containing microvesicles regulating inflammation in association with atherosclerotic disease[J].Cardiovasc Res,2013,100(1):7-18.
[13] Mitchell P S,Parkin R K,E M Kroh,et al.Circulating microRNAs as stable blood-based markers for cancer detection[J].Proc NatlAcad Sci USA,2008,105(30):10513-10518.
[14] Lemoinne S,Thabut D,Housset C,et al.The emerging roles of microvesicles in liver diseases[J].Nat Rev Gastroenterol Hepatol,2014,11(6):350-361.
[15] Arroyo J D,Chevillet J R,Kroh E M,et al.Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma[J].Proc Natl Acad Sci USA,2011,108(12):5003-5008.
[16] Pirola C J,Fernández Gianotti T,Castaño G O,et al.Circulating microRNA signature in non-alcoholic fatty liver disease:from serum non-coding RNAs to liver histology and disease pathogenesis[J].Gut,2015,64(4):800-812.
[17] Mofrad P,Contos M J,Haque M,et al.Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values[J].Hepatology,2003,37(6):1286-1292.
[18] Molleston J P,Schwimmer J B,Yates K P,et al.Histological abnormalities in children with nonalcoholic fatty liver disease and normal or mildly elevated alanine aminotransferase levels[J].J Pediatr,2014,164(4):707-713.
[19] Su Y W,Chen X,Jiang Z Z,et al.A panel of serum micro RNAs as specific biomarkers for diagnosis of compound-and herb-induced liver injury in rats[J].PLoS ONE,2012,7(5):e37395.
[20] Starkey Lewis P J,Dear J,Platt V,et al.Circulating micro RNAs as potential markers of human drug-induced liver injury[J].Hepatology,2011,54(5):1767-1776.
[21] Waidmann O,Köberle V,Brunner F,et al.Serummicro RNA-122 predicts survival in patients with liver cirrhosis[J].PLoS ONE,2012,7(9):e45652.
[22] Koberle V,Kronenberger B,Pleli T,et al.Serum micro-RNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma[J].Eur J Cancer,2013,49(16):3442-3449.
[23] Wang K,Zhang S,Marzolf B,et al.Circulating microRNAs,potential biomarkers fordrug-induced liver injury[J].Proc Natl Acad Sci USA,2009,106(11):4402-4407.
[24] Bihrer V,Friedrich-Rust M,Kronenberger B,et al.Serum miR-122 as a biomarker of necroinflammation in patients with chronic hepatitis C virus infection[J].Am J Gastroenterol,2011,106(9):1663-1669.
[25] Wang B,Howel P,Bruheim S,et al.Systematic evaluation of three microRNA profiling platforms:microarray,beads array and quantitative real-time PCR array[J].PLoS ONE,2011,6(2):e17167.
[26] Kim H,Choi J,Cho M,et al.A PNA microarray platform for miRNA expression profiling using on-chip labeling technology[J].Biochip J,2012,6(1):25-33.
[27] Chakraborty C,Wen Z H,Agoramoorthy G,et al.Therapeutic microRNA delivery strategies with special emphasis on cancer therapy and tumorigenesis:current trends and future challenges[J].Current Drug Metabolism,2016,17(999):1-9.
[28] Agostini M,Knight R A.MiR-34:from bench to bedside[J].Oncotarget,2014,5(4):872-881.

备注/Memo

收稿日期:2017-05-22。
基金项目:浙江省科技计划项目(2016F10007);浙江中医药大学校级科研基金项目(2017ZY23)。
作者简介:徐志伟(1988-),男,研究实习员,医学硕士。研究方向:中药药理与毒理学。
通讯作者:郑高利(1963-),男,研究员,医学博士。研究方向:中药药理学。E-mail:gaoli-z@126.com

更新日期/Last Update: 1900-01-01